Genentech efalizumab is Raptiva
Executive Summary
Genentech/Xoma change name of psoriasis agent Xanelim to Raptiva in order to "limit potential confusion" with Idec's non-Hodgkin's lymphoma agent Zevalin. The efalizumab BLA filing was delayed after a pharmacokinetic study comparing Xoma-produced study drug to Genentech-produced commercial drug was not found to be comparable (1"The Pink Sheet" April 8, In Brief). Genentech hopes to file the BLA before the end of 2002...
You may also be interested in...
Genentech/Xoma Xanelim BLA delay
Genentech/Xoma's Xanelim (efalizumab) BLA filing will be delayed beyond summer 2002, companies announce April 5. A pharmacokinetic study comparing Genentech-produced to Xoma-produced drug did not achieve statistical definition of comparability. Genentech had projected a summer 2002 BLA filing for the psoriasis therapy (1"The Pink Sheet" Jan. 21, p. 32)...
Health And Wellness Trademark Review 2 March, 2021
Trademarks are registered and published for opposition with the US Patent and Trademark Office and are published weekly in the agency's Official Gazette.
In Order Shutting Down New York Supplement Firm, Federal Judge Also Criticizes FDA’s Calculations
Judge ordering permanent injunction against Confidence USA on a complaint filed in 2019 questioned FDA's calculations for requiring the firm to recall and destroy all products it had distributed since February 2018.
Need a specific report? 1000+ reports available
Buy Reports
Register for our free email digests: